Position in ALKS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$15,321,078
New position
Shares Held
292,387
first reported quarter
Ownership
0.174%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#74
of 423 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GW&K Investment Management, LLC holds $191,069,124 across 11 Drug Manufacturers - Specialty & Generic names. ALKS ranks #4 (8.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
567,421 | $95,633,135 | |
| 2 | SUPN |
Supernus Pharmaceuticals, Inc.
|
1,037,242 | $48,242,125 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
3,171,113 | $31,711,130 | |
| 4 | ALKS |
Alkermes plc.
This page
|
292,387 | $15,321,078 | |
| 5 | VTRS |
Viatris Inc
|
3,133 | $49,752 | |
| 6 | ZTS |
Zoetis Inc.
|
516 | $37,079 | |
| 7 | HLN |
Haleon plc
|
3,796 | $35,416 | |
| 8 | TEVA |
Teva Pharmaceutical Industries Ltd
|
495 | $16,770 |
All Filings in ALKS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,321,078 | 292,387 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||